tetano
Editor, Senior Moderator
Clin Transplant
. 2021 Jul 28.
doi: 10.1111/ctr.14443. Online ahead of print.
Low mortality in SARS-CoV-2 infected heart transplant recipients at a single center
Jason M Duran[SUP] 1 [/SUP], Masihullah Barat[SUP] 1 [/SUP], Andrew Y Lin[SUP] 1 [/SUP], Kevin R King[SUP] 1 [/SUP], Barry Greenberg[SUP] 1 [/SUP], Eric D Adler[SUP] 1 [/SUP], Saima Aslam[SUP] 2 [/SUP]
Affiliations
Abstract
Immunosuppressed heart transplant (HT) recipients are thought to be at higher risk of infection and mortality from SARS-CoV-2 infection coronavirus disease 2019 (COVID-19), however evidence guiding management of HT patients are limited. Retrospective search of electronic health records from February 2020 - February 2021, identified 28 HT recipients out of 400 followed by UC San Diego who tested positive for SARS-CoV-2. Patient demographics, COVID-19 directed therapies, hospital course and outcomes were compared to control HT recipients who tested negative for SARS-CoV-2 during the same period (n = 80). Among 28 HT recipients who tested positive for SARS-CoV-2, 15 were admitted to the hospital and 13 were monitored closely as outpatients. Among inpatients, five developed severe illness and two died (7% mortality). Nine patients were treated with remdesivir, and four received dexamethasone and remdesivir. Two outpatients received neutralizing monoclonal antibody therapy and one outpatient received dexamethasone for persistent dyspnea. Immunosuppressed HT recipients, especially Hispanic patients and patients with higher body mass index, were at greater risk of infection and mortality from COVID-19 than the general population. Use of remdesivir and dexamethasone may have improved outcomes in our HT recipients compared to HT recipients at other centers. This article is protected by copyright. All rights reserved.
. 2021 Jul 28.
doi: 10.1111/ctr.14443. Online ahead of print.
Low mortality in SARS-CoV-2 infected heart transplant recipients at a single center
Jason M Duran[SUP] 1 [/SUP], Masihullah Barat[SUP] 1 [/SUP], Andrew Y Lin[SUP] 1 [/SUP], Kevin R King[SUP] 1 [/SUP], Barry Greenberg[SUP] 1 [/SUP], Eric D Adler[SUP] 1 [/SUP], Saima Aslam[SUP] 2 [/SUP]
Affiliations
- PMID: 34320235
- DOI: 10.1111/ctr.14443
Abstract
Immunosuppressed heart transplant (HT) recipients are thought to be at higher risk of infection and mortality from SARS-CoV-2 infection coronavirus disease 2019 (COVID-19), however evidence guiding management of HT patients are limited. Retrospective search of electronic health records from February 2020 - February 2021, identified 28 HT recipients out of 400 followed by UC San Diego who tested positive for SARS-CoV-2. Patient demographics, COVID-19 directed therapies, hospital course and outcomes were compared to control HT recipients who tested negative for SARS-CoV-2 during the same period (n = 80). Among 28 HT recipients who tested positive for SARS-CoV-2, 15 were admitted to the hospital and 13 were monitored closely as outpatients. Among inpatients, five developed severe illness and two died (7% mortality). Nine patients were treated with remdesivir, and four received dexamethasone and remdesivir. Two outpatients received neutralizing monoclonal antibody therapy and one outpatient received dexamethasone for persistent dyspnea. Immunosuppressed HT recipients, especially Hispanic patients and patients with higher body mass index, were at greater risk of infection and mortality from COVID-19 than the general population. Use of remdesivir and dexamethasone may have improved outcomes in our HT recipients compared to HT recipients at other centers. This article is protected by copyright. All rights reserved.